About Grifols
Grifols is a publicly listed company based in Barcelona (Spain) founded in 1909. Plasma-derived therapies are developed to treat multiple diseases. The company has 23,830 employees. Grifols has completed 8 acquisitions, including Alkahest, Araclon and Biotest. Its chief executive, as recorded, is Raimon Grifols Roura. Its website grifols.com draws about 350 thousand monthly visits. Its Indian entity Grifols India Healthcare Private Limited reported revenue of ₹152 Cr. Its focus areas include Life Sciences, Immunology, Drugs and Diversified.
Company details
Grifols was founded in 1909 in Barcelona, Spain, and operates in the biopharmaceutical sector. Plasma-derived medicines and transfusion medicines are produced for therapeutic areas including neurology, immunology, hepatology, intensive care, pulmonology, hematology, and infectious diseases. Operations focus on treating a broad range of conditions through these specialized therapies, with global reach from its European base.
- Indian entity revenue₹152 Cr
FY 2025 · +31% YoY
- Indian entity net profit₹21.75 Cr
FY 2025 · 14% margin
- Indian entity EBITDA₹32.35 Cr
FY 2025 · 21% margin
- Latest Funding Round$21M (USD), Grant
Jan 2025
- Investors
- Employee Count23,830
- Investments & AcquisitionsAlkahest
& 7 more
Associated legal entities of Grifols
Grifols operates through Grifols India Healthcare Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Grifols India Healthcare Private Limited CIN U74999HR2014FTC074802 | Active | 20 Dec 2014 | Gurgaon, Haryana | ₹152 Cr | 12 | 3 | View details |
Apps and channels of Grifols
its YouTube channel Grifols has 1.65K subscribers and 30 videos.
Videos from Grifols
The most watched videos on Grifols's YouTube channel, Grifols (1.65K subscribers). Click a video to play it here.
More on Grifols.
Funding Insights of Grifols
- Total Rounds 1
- Last Round Grant — $21M
- First Round $21M
(Jan 2025)
- Investors Count 1
All 1 funding rounds of Grifols with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $21M | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Grifols
Grifols has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include The Michael J. Fox Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States |
Investor details for Grifols
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Grifols India Healthcare Private Limited (Grifols)
Grifols India Healthcare Private Limited is the primary company behind Grifols. The board of Grifols India Healthcare Private Limited currently have 3 directors; the longest-serving is Manpreet Singh, appointed in 2022. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Manpreet Singh DIN 06591951 | Director | 02 Dec 2022 | 3 yrs 11 mo | Grifols India Healthcare Private Limited |
| Santiago Gonzã¡Lez Orti DIN 09844494 | Director | 30 Dec 2022 | 3 yrs 10 mo | Grifols India Healthcare Private Limited |
| Irene Roche Font DIN 10192021 | Director | 06 Jun 2023 | 3 yrs 5 mo | Grifols India Healthcare Private Limited |
People of Grifols
219 people are tracked at Grifols (89 in leadership, 16 in board & advisors, 114 in team); the tracked headcount is 23,830.
| Name | Role | Group |
|---|---|---|
Raimon Grifols Roura | Co-CEO | Leadership |
Victor Grifols Deu | Co-CEO | Leadership |
Gary Bouton | Regional Sales Director - Pulmonary | Leadership |
Steffen Mager | Vice President Biopharma Sales & Commercial Operations Europe | Leadership |
Víctor Grífols Deu | Co-CEO | Leadership |
Raimon Grífols Roura | Co-CEO | Leadership |
Thomas Ardiles | Global Medical Director Pulmonary And Critical Care | Leadership |
Deborah Gelinas | Medical Director | Leadership |
Bernie Bao | Director, Commercial Technical Support，g.china & APAC | Leadership |
Mary F Pascucci Do | Laboratory Director/center Medical Director - Biomat | Leadership |
Robert Morell | Center Medical Director And Laboratory Director Grifols -eglin Fort Walton Beach Biomat | Leadership |
Ryan Means | Regional Sales Director | Leadership |
Jim Martinec | Director, Head Of North America Customer Marketing | Leadership |
Jose L. Fernández Sevillano | Head Of Market Access - Iberia | Leadership |
Mary Davis | Regional Sales Director | Leadership |
Sílvia Solé Suñer | Director, Dxcts Global Response & Training | Leadership |
June Davis | Vp, Global Medical Affairs | Leadership |
Sarah Bonza M.D. | Center Medical Director | Leadership |
Janie Myers do Dfacos | Chief Medical Director | Leadership |
Jill Ward M.D. | Laboratory And Medical Director | Leadership |
199 more people are available in the full profile.
Complete people profiles for Grifols
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Grifols
Grifols is a publicly listed company on the BME with ticker symbol GRF in Spain, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Jun 2011
- Listed onNASDAQ: GRFS
- Listed entityGrifols, S.A. Class A
- Exchange sectorHealth technology
- ISINES0171996087
- Share price9.84 EUR (+0.41% on the day) · 2026-10-14
- Market capitalisation5,813,975,613.00 EUR
- Price to earnings14.8
- EPS (diluted, trailing year)0.66 EUR
- Dividend yield1.92%
- Volume (last session)389,842
Financials of Grifols
Figures of Grifols India Healthcare Private Limited, the primary company behind Grifols, for FY 2025. Revenue was ₹152 Cr (+31% year on year). Net profit was ₹21.75 Cr (14% margin). EBITDA was ₹32.35 Cr (21% margin). Revenue has grown at a compounded annual rate of +25% over three years and +32% over five years.
- ₹152 CrRevenue · FY 2025 · +31% YoY
- ₹21.75 CrNet profit · 14% margin
- ₹32.35 CrEBITDA · 21% margin
- ₹1.3 LakhPaid-up capital
- 12Employees (provident fund records)
- +25%Revenue CAGR, 3 years
- +32%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 7.52B EUR | 402.0M EUR | 1.69B EUR |
| 2024 | 7.21B EUR | 156.9M EUR | 1.56B EUR |
| 2023 | 6.59B EUR | 42.3M EUR | 1.14B EUR |
| 2022 | 6.06B EUR | 208.3M EUR | 1.09B EUR |
| 2021 | 4.93B EUR | 188.7M EUR | 917.5M EUR |
Balance sheet, profit and loss, cash flow and ratios of Grifols India Healthcare Private Limited are on its company page.
Detailed financial statements for Grifols
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Grifols
Grifols has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Alkahest, Araclon and Biotest.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of plasma proteins and drugs for immunology and hematology | biotest.com | Dreieich, Germany | 1946 | Sep 2021 | •••• | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | gigagen.com | San Francisco, United States | 2011 | Mar 2021 | $80M | |
Therapies derived from blood to treat neurological diseases. | alkahest.com | San Carlos, United States | 2014 | Sep 2020 | $146M | |
Biotherapeutic products for immunology and liver therapy are manufactured. | biotestpharma.com | Boca Raton, United States | 2007 | Aug 2018 | $286M | |
Web and handheld software is supplied to hospitals and pharmacies. | medkeeper.com | Denver, United States | 2001 | Jan 2018 | •••• | |
Robotic automation for compounding intravenous treatments is provided. | kiro-robotics.com | Arrasate, Spain | 2010 | Sep 2014 | $27.05M | |
Develop immunotherapy and diagnostic tests for neurodegenerative disorders | araclon.com | Zaragoza, Spain | 2004 | Mar 2012 | •••• | |
Plasma-derived therapies are developed for immunology, pulmonology, and related fields. | talecris.com | Durham, United States | 2005 | Jun 2010 | $4B |
Complete acquisition details for Grifols
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Grifols
11 dated milestones of Grifols across 116 years, from founding to its latest funding, stage changes and deals.
- Founded Grifols is founded.
- Acquisition Acquires Talecris Biotherapeutics.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Araclon.
- Acquisition Acquires KIRO Robotics.
- Acquisition Acquires MedKeeper.
- Acquisition Acquires Biotest Pharmaceuticals.
- Acquisition Acquires Alkahest.
- Acquisition Acquires GigaGen.
- Acquisition Acquires Biotest.
- Funding First funding round of $21.0M.
Web traffic of Grifols
The website of Grifols (grifols.com) receives about 349.5K visits a month and ranks #158,455 among all websites worldwide, #4,950 in Health.
- Monthly visits349.5K
▲ 30.3% vs previous month
- Unique visitors102K
per month
- Global rank#158,455
among all websites
- Category rank#4,950
Health · Health
- Bounce rate45%
- Pages per visit3.1
- Average visit2 min 07 sec
- DevicesDesktop 45% · Mobile 56%
Websites whose visitors overlap most with Grifols. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
grifolsplasma.com | grifolsplasma.com | 100% | #115,061 | – | |
| nbninfusions.com | 76% | View details | |||
nursingjobs.com | nursingjobs.com | 66% | – | ||
| baxter.com | 63% | 401.8K | #127,908 | View details | |
lambdasrl.it | lambdasrl.it | 59% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Grifols
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Grifols
Complete news archive for Grifols
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Grifols
Grifols was founded in 1909 and raised its 1st funding round 116 years after it was founded.
Grifols is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Raimon Grifols Roura is the CEO of Grifols, as recorded in our data.
Grifols has 23,830 employees.
The primary company behind Grifols, Grifols India Healthcare Private Limited, reported revenue of ₹152 Cr for FY 2025, up 31% year on year.
Grifols was founded in 1909 in Barcelona, Spain, and operates in the biopharmaceutical sector. Plasma-derived medicines and transfusion medicines are produced for therapeutic areas including neurology, immunology, hepatology, intensive care, pulmonology, hematology, and infectious diseases. Operations focus on treating a broad range of conditions through these specialized therapies, with global reach from its European base.
Yes, Grifols is publicly traded on BME under the ticker symbol GRF.
Grifols has 1 investor. Key investors include The Michael J. Fox Foundation.
Grifols operates through Grifols India Healthcare Private Limited.
The legal entities of Grifols currently have 3 directors, including Irene Roche Font, Santiago Gonzã¡Lez Orti, Manpreet Singh.
The website of Grifols receives about 350 thousand visits a month and ranks #158,455 among all websites worldwide.